Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

BACKGROUND: The MAPK pathway is an emerging target across a number of adult and pediatric tumors. Targeting the downstream effector of MAPK, MEK1, is a proposed strategy to control the growth of MAPK-dependent tumors. OBJECTIVE: iMATRIX-cobi assessed the safety, pharmacokinetics, and anti-tumor acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Trippett, Tanya, Toledano, Helen, Campbell Hewson, Quentin, Verschuur, Arnauld, Langevin, Anne-Marie, Aerts, Isabelle, Howell, Lisa, Gallego, Soledad, Rossig, Claudia, Smith, Amy, Patel, Darshak, Pereira, Leonardo R., Cheeti, Sravanthi, Musib, Luna, Hutchinson, Katherine E., Devlin, Clare, Bernardi, Ronald, Geoerger, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217999/
https://www.ncbi.nlm.nih.gov/pubmed/35715627
http://dx.doi.org/10.1007/s11523-022-00888-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217999/
https://www.ncbi.nlm.nih.gov/pubmed/35715627
http://dx.doi.org/10.1007/s11523-022-00888-9

Ejemplares similares